TL;DR
Get business pricing on office and shipping supplies
- Business-only prices and quantity discounts
- Tax-exempt purchasing
- Multiple users, one account, clear invoices
Sobi’s Nomination Committee has proposed Börje Ekholm for election as a board member and chair at the company’s 2027 Annual General Meeting. Current chair David Meek will not stand for re-election and is expected to remain in the role until May 2027; shareholders have not yet voted on the proposal.
Sobi’s Nomination Committee has proposed that Börje Ekholm be elected as a board member and chair at the company’s 2027 Annual General Meeting, following current chair David Meek’s decision not to seek re-election. The proposal is subject to a shareholder vote; Meek is due to continue in the role until May 2027.
Meek informed the Nomination Committee that he would not stand for another term at the 2027 AGM. He has served as a Sobi board member and chair since December 2024. The company said he will remain chair for the rest of his current term, which ends in May 2027.
Ekholm recently stepped down as CEO of Ericsson. Sobi’s announcement says he has more than 30 years of experience in technology, investment management and international business leadership, including previous chief executive roles at Patricia Industries and Investor AB. He is chair of Trimble and is due to join Nasdaq Inc.’s board effective November 1, 2026.
The committee’s full set of proposals for the AGM will be published in due time before the meeting, Sobi said. The announcement was made on October 29, 2026, and identified the Nomination Committee’s recommendation; it did not report a completed appointment or a shareholder decision.
A Leadership Change at Sobi
The proposal sets out a potential change in oversight at the board level of a listed biopharmaceutical company focused on rare diseases. If shareholders elect him, Ekholm would succeed Meek as chair after the current chair’s term ends in May 2027. The chair leads the board’s work, while company management remains responsible for day-to-day operations.
Ekholm’s background spans corporate leadership, investment and board roles, and Sobi says he was involved in the company’s creation from an owner perspective. That history could give him familiarity with the business and its development, but the announcement does not set out a specific strategy or policy change tied to the proposed appointment. The significance for investors and other stakeholders is therefore the potential change in board leadership, not a reported change in Sobi’s operating plans.
Sobi reported revenue of SEK 28 billion in 2025 and said it had about 2,000 employees across several regions. Those company figures provide scale for the governance decision; they do not establish that the proposed chair would cause future financial or commercial results.
Products Worth Considering
Dell UltraSharp U2725QE 27-Inch 4K UHD IPS Black Monitor
FLEXISPOT EN1 Electric Standing Desk, 48 x 24 in, Black
Apple iPad Air (4th Generation, 10.9-inch, Wi-Fi, 256GB) – Space Gray
As an affiliate, we earn on qualifying purchases.
Meek’s Term and Ekholm’s Experience
Meek became both a board member and chair in December 2024. Sobi’s announcement credits the company with strong growth and shareholder returns during his tenure, as well as expanded access to medicines through launches and indication extensions and a strengthened clinical development pipeline. These are the company’s descriptions of performance under his leadership, rather than independently detailed measurements in the announcement.
Ekholm’s earlier roles include CEO of Investor AB, where, according to Sobi, he was involved in the creation of Sobi through the merger of Biovitrum and Swedish Orphan International. His prior board assignments include Alibaba, Husqvarna, Nasdaq, Scania and WM Data; he previously chaired Nasdaq and WM Data. Sobi also says he serves as a board adviser to Mars and adviser to Ericsson’s CEO.
The company is Swedish Orphan Biovitrum AB, which operates under the name Sobi and is listed on Nasdaq Stockholm. The proposed election follows the standard shareholder-governance process: a nomination committee recommends candidates, and shareholders decide at the AGM.
Ekholm has not yet been elected, and the committee has not announced the complete slate of AGM proposals. Shareholders will make the decision at the 2027 meeting. Sobi’s announcement does not specify the AGM date beyond the year, or provide further details on the voting process or any conditions attached to the recommendation.
The release also does not explain Meek’s reasons for declining to stand again, beyond saying he informed the committee of his decision. It provides no detailed breakdown of the performance claims made about his tenure and does not describe any planned shift in strategy under a potential new chair. Those matters should not be inferred from the nomination announcement.
The 2027 AGM Vote
Sobi says it will publish the Nomination Committee’s complete proposals ahead of the 2027 AGM. At that meeting, shareholders are expected to consider whether to elect Ekholm as both a board member and chair. Until the vote, Meek is expected to continue as chair through the remainder of his term, ending in May 2027.
The company has not supplied a specific AGM date in the announcement. Further details, including the full board slate and the formal meeting materials, are expected before shareholders vote.
Key Questions
Has Börje Ekholm been appointed as Sobi’s chair?
No. Sobi’s Nomination Committee has proposed him for election. Shareholders must vote on the proposal at the 2027 AGM.
When will David Meek leave the chair role?
Meek is expected to remain chair until his current term ends in May 2027. He has said he will not stand for re-election at that year’s AGM.
What experience does Ekholm bring?
Sobi cites more than 30 years in technology, investment management and international business leadership. His roles include CEO of Ericsson, Patricia Industries and Investor AB, as well as board positions at several companies.
When will Sobi shareholders vote?
The vote is expected at Sobi’s 2027 Annual General Meeting. The announcement did not give a specific meeting date; the company said full committee proposals would be published before the AGM.
Source: prnewswire.com
